NewAmsterdam Pharma(NASDAQ) NAMSW

Market CapN/A

Since IPO (2021)+123%

5 Year+1,963%

1 Year+19%

1 Month-15%

$16.51

+3.19%

+0.51Today

NewAmsterdam Pharma last closing stock price
Metric	Price	Date
Last close	USD 16.51	2026-08-25

NewAmsterdam Pharma stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+3.19%	USD 16.00	2026-08-18
1 month	-14.81%	USD 19.38	2026-07-22
3 month	-33.96%	USD 25.00	2026-05-27
Year to date	-28.22%	USD 23.00	2025-12-31
1 year	+18.97%	USD 13.88	2025-08-25
3 year	+725.5%	USD 2.00	2023-08-23
5 year	+1,963.49%	USD 0.80	2021-08-26
Since inception	+122.64%	USD 7.42	2021-02-08

NewAmsterdam Pharma Financials at a Glance

Market Cap

N/A

Revenue (TTM)

$7.12M

Net Income (TTM)

-$259.50M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

0.94 (Low)

Dividend

$0.00

Beta (Volatility)

0.94 (Low)

Price

$16.51

Volume

200

Open

$16.51

Price

$16.51

Volume

200

Open

$16.51

Previous Close

$16.51

Daily Range

$16.51 - $16.51

52-Week Range

$12.69 - $30.45

Estimated Earnings Date

Nov 11, 2026

Dividend

$0.00

Beta (Volatility)

0.94 (Low)

Price

$16.51

Volume

200

Open

$16.51

Previous Close

$16.51

Daily Range

$16.51 - $16.51

52-Week Range

$12.69 - $30.45

Estimated Earnings Date

Nov 11, 2026

NAMSW News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V. is a biopharmaceutical firm focused on developing innovative therapeutic options for metabolic diseases. The company is advancing its primary experimental treatment, obicetrapib, which targets Cholesteryl Ester Transfer Protein (CETP) to improve cholesterol levels.

Products and Services

Obicetrapib: A selective CETP inhibitor in clinical trials
Research and development of metabolic disease therapies
Innovative approaches to cholesterol management

Growth Outlook

Strong pipeline with ongoing clinical trials for obicetrapib
Potential market expansion in metabolic disease treatments
Increasing demand for effective cholesterol management solutions

Financial Highlights

Q2 2026 revenue of $3.7 million, up from $3.04 million in Q1 2026
Cash and short-term investments total $633.85 million as of Q2 2026
Operating expenses of $68.57 million in Q2 2026, reflecting ongoing R&D investments

NewAmsterdam Pharma Company N.V. is positioned in the biotechnology sector, focusing on innovative solutions for metabolic diseases. The company's lead product, obicetrapib, has shown promise in clinical trials, indicating a potential breakthrough in cholesterol management. With a robust cash position, the company is well-equipped to continue its research and development efforts. Recent financial data highlights a steady increase in revenue, suggesting growing interest in its therapeutic offerings. The ongoing clinical trials and the potential for market expansion present a compelling narrative for future growth.

AI Generated • Aug 19, 2026

Industry

Biotechnology

Sector

Health Care

Headquarters

Naarden, NH 1411 DC, NL

NAMSW Financials

Key Financial Metrics (TTM)

Gross Margin

92.15%

Operating Margin

-3432.20%

Net Income Margin

-3644.21%

Return on Equity

-38.33%

Return on Capital

-33.01%

Return on Assets

-36.84%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/A

Shares Outstanding

Volume

200

Avg. Volume

1.19K

Financials (TTM)

Gross Profit

$6.56M

Operating Income

-$244.41M

EBITDA

-$254.88M

Operating Cash Flow

-$143.46M

Capital Expenditure

-$260.00K

Free Cash Flow

-$143.72M

Cash & ST Invst.

$633.85M

Total Debt

$82.00K

NewAmsterdam Pharma Performance Analysis

NewAmsterdam Pharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	-98.2%
Q4	2025-12-31	-90.8%
Q1	2026-03-31	9400.0%
Q2	2026-06-30	21.7%

NewAmsterdam Pharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	-306.7%
Q4	2025-12-31	-6.6%
Q1	2026-03-31	38.5%
Q2	2026-06-30	-30.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

$3.70M

-80.7%

Gross Profit

$3.70M

-80.7%

Gross Margin

100.00%

N/A

Market Cap

N/A

Market Cap/Employee

N/A

Employees

100

N/A

Net Income

-$64.14M

-269.4%

EBITDA

-$59.69M

-244.7%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

$633.85M

-14.2%

Total Debt

$82.00K

-75.0%

Accounts Receivable

$24.00M

N/A

Inventory

$0.00

N/A

Long Term Debt

$56.00K

-45.6%

Short Term Debt

$26.00K

-88.4%

Return on Assets

-36.84%

N/A

Return on Invested Capital

-38.70%

N/A

Free Cash Flow

-$39.29M

-4.1%

Operating Cash Flow

-$39.21M

-4.1%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

SRRKScholar Rock Holding Corporation

SRRKScholar Rock Holding Corporation$56.80-1.73%

VCYTVeracyte, Inc.

VCYTVeracyte, Inc.$43.19-0.35%

IDYAIDEAYA Biosciences, Inc.

IDYAIDEAYA Biosciences, Inc.$40.10-0.02%

KNSAKiniksa Pharmaceuticals International, plc

KNSAKiniksa Pharmaceuticals International, plc$78.63+0.70%

ZLABZai Lab Limited

ZLABZai Lab Limited$25.46-2.38%

FOLDAmicus Therapeutics, Inc.

FOLDAmicus Therapeutics, Inc.$14.49+0.00%

TARSTarsus Pharmaceuticals, Inc.

TARSTarsus Pharmaceuticals, Inc.$74.24+3.46%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

WETOWetour Robotics

WETOWetour Robotics$5.48-0.04%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$71.92+0.00%

IBITiShares Bitcoin Trust

IBITiShares Bitcoin Trust$44.67+0.02%

INTCIntel

INTCIntel$89.51+0.00%

NVDANvidia

NVDANvidia$220.78+0.01%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$9.97+0.11%

TLTiShares Trust - iShares 20+ Year Treasury Bond ETF

TLTiShares Trust - iShares 20+ Year Treasury Bond ETF$82.52-0.00%

Questions About NAMSW

What is the current price of NewAmsterdam Pharma?

NewAmsterdam Pharma is trading at $16.51 per share.

What is the 52-week range for NewAmsterdam Pharma?

Over the past 52 weeks, NewAmsterdam Pharma has traded between $12.69 and $30.45.

How much debt does NewAmsterdam Pharma have?

NewAmsterdam Pharma total debt is unavailable.

How much cash does NewAmsterdam Pharma have on hand?

NewAmsterdam Pharma does not have cash on hand data available.

What is NewAmsterdam Pharma’s dividend yield?

NewAmsterdam Pharma does not currently have a dividend yield.

NewAmsterdam Pharma(NASDAQ) NAMSW

NewAmsterdam Pharma Financials at a Glance

NAMSW News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About NewAmsterdam Pharma

NAMSW Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

NewAmsterdam Pharma Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About NAMSW

What is the current price of NewAmsterdam Pharma?

What is the 52-week range for NewAmsterdam Pharma?

How much debt does NewAmsterdam Pharma have?

How much cash does NewAmsterdam Pharma have on hand?

What is NewAmsterdam Pharma’s dividend yield?

Premium Investing Services